All In Biotech

Drug Trial Radar · NCT06490991

Comparison of HRS-5965 Capsules and Tablets in Healthy Subjects

A Clinical Study Evaluating the Relative Bioavailability of HRS-5965 Capsules and Tablets in Healthy Subjects .

Last checked: Nov 20, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jul 17, 2024

Primary completion

Aug 6, 2024

Study completion Sep 10, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is designed as a single-center, randomized, open-label, cross-over phase I clinical trial with the intention of recruiting 16 healthy subjects.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria,IgA Nephropathy

Interventions

  • HRS-5965 tablets;HRS-5965 capsulesDrug

    Medication regimen: 1 Drug: HRS-5965 tablets Medication regimen: 2 Drug: HRS-5965 capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The relative bioavailability (Fr) values between HRS-5965 capsules and HRS-5965 tablets taken on an empty stomachTime frame: 0-144hours
  2. Relative bioavailability (Fr) values of HRS-5965 capsules taken on an empty stomachTime frame: 0-144hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ZhongShan Hospital FuDan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.